Dobutamine stress echocardiography and the effects of trimetazidine on left ventricular dysfunction in patients with coronary artery disease.
Trimetazidine, a metabolic agent that is opening the way to a new class of 3-ketoacyl coenzymeA thiolase inhibitors, has been shown to improve exercise tolerance and increase the ischaemic threshold in patients with effort angina, both in monotherapy or in combination with other anti-anginal drugs. The aim of this study was to assess the effects of oral trimetazidine on the ischaemic threshold and left ventricular dysfunction of patients with coronary artery disease. Dobutamine stress echocardiography was used, a technique that allows direct visualisation of localised left ventricular dysfunction that occurs as a result of ischaemia. Dobutamine increases heart rate and contractility thus augmenting oxygen demand. In coronary artery disease, this increased demand leads to metabolic changes responsible for decreased wall thickness and abnormal wall motion.
Chierchia
S L
SL
Department of Cardiology, Ospedale S. Martino, Largo Giovanna Benzi, Genoa, Italy. segicardioz@smarfino.ge.it
D000368:Aged; D002316:Cardiotonic Agents; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000503:physiopathology*; D018592:Cross-Over Studies; D004280:Dobutamine; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014292:Trimetazidine / Q000494:pharmacology*; D014463:Ultrasonography; D014665:Vasodilator Agents / Q000494:pharmacology*; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy; D016277:Ventricular Function, Left / Q000187:drug effects*
D002316:Cardiotonic Agents; D014665:Vasodilator Agents; D004280:Dobutamine; D014292:Trimetazidine